Palisade Bio (PALI) Non-Current Assets (2010 - 2026)
Palisade Bio (PALI) posted quarterly Non-Current Assets of $72000.0 for Q1 2026, down 76.24% year-over-year from $303000.0 in Q1 2025, and down 41.46% quarter-over-quarter from $123000.0 in Q4 2025.
Palisade Bio (PALI) Non-Current Assets (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Non-Current Assets for 17 consecutive years, with $72000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 76.24% year-over-year to $72000.0; the TTM figure through Mar 2026 stood at $560000.0 (down 67.33% YoY), while the FY2025 annual figure was $123000.0, down 68.13% from the prior year.
- Non-Current Assets eased to $72000.0 in Q1 2026 per PALI's latest filing, from $123000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.1 million in Q3 2022 and bottomed at $72000.0 in Q1 2026.
- Historically, Non-Current Assets has averaged $523000.0 across 5 years, with a median of $466000.0 in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 935.87% — and 2026, when it slumped 76.24%.
- Palisade Bio's Non-Current Assets stood at $1.0 million in 2022, then decreased by 29.71% to $724000.0 in 2023, then sank by 46.69% to $386000.0 in 2024, then sank by 68.13% to $123000.0 in 2025, then sank by 41.46% to $72000.0 in 2026.
- Business Quant data shows PALI's Non-Current Assets at $72000.0 in Q1 2026, $123000.0 in Q4 2025, and $145000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | 55,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55,000.00 |
| Mar 31, 2026 | 72,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | 145,000.00 |
| Jun 30, 2025 | 220,000.00 |
| Mar 31, 2025 | 303,000.00 |
| Dec 31, 2024 | 386,000.00 |
| Sep 30, 2024 | 466,000.00 |
| Jun 30, 2024 | 559,000.00 |
| Mar 31, 2024 | 639,000.00 |
| Dec 31, 2023 | 724,000.00 |
| Sep 30, 2023 | 801,000.00 |
| Jun 30, 2023 | 879,000.00 |
| Mar 31, 2023 | 953,000.00 |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 391,000.00 |
| Mar 31, 2022 | 92,000.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 182,000.00 |